IPP Bureau
Centre intensifies push for zero leprosy transmission
By IPP Bureau - June 13, 2026
Health Ministry reviews progress, highlights targeted interventions in high-burden states, and calls for stronger surveillance and stigma reduction to achieve a leprosy-free India
India validates first indigenous HPV DNA test for cervical cancer screening
By IPP Bureau - June 13, 2026
Molbio Diagnostics' Truenat HPV-HR Plus becomes the world's first formally validated reduced-valency HPV test, meeting WHO-IARC standards
Ryvu advances romaciclib program as FDA clears AML trial expansion
By IPP Bureau - June 13, 2026
The regulatory decision follows promising results from RIVER-81
Novo Nordisk confirms cyber breach after hackers access personal data
By IPP Bureau - June 13, 2026
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
UK approves Wegovy pill in major shift in obesity treatment options
By IPP Bureau - June 13, 2026
Approval is based on results from the phase 3 OASIS 4 clinical trial
FDA clears Wave Neuroscience’s AI-guided brain stimulation platform for PTSD treatment
By IPP Bureau - June 13, 2026
MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
Rayat Bahra University, Shukra Pharma launch Rs. 10 lakh seed fund to back student startups
By IPP Bureau - June 13, 2026
Partnership will provide funding, incubation, mentorship, and industry exposure for ventures in healthcare, pharmaceuticals, biotechnology, medical technology, and agriculture
Relmada Therapeutics bolsters Sepranolone Program with Michael Quirk as Senior Advisor
By IPP Bureau - June 13, 2026
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
WHO SEARO, George Institute partner to advance AI-driven digital health solutions for NCDs
By IPP Bureau - June 13, 2026
Two-year collaboration aims to strengthen primary healthcare systems, generate real-world evidence, and support responsible adoption of AI and digital health technologies across South-East Asia
India’s pharma market to hit US$ 130 billion, exports US$ 80 billion by 2030: ASSOCHAM
By IPP Bureau - June 12, 2026
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
Biopharma SHAKTI envisages launch of 100 biologics by 2047: Anupriya Patel
By IPP Bureau - June 12, 2026
The union minister spoke at the 2nd Pharma Summit & Awards 2026 organised by ASSOCHAM in New Delhi
Major UK study to evaluate newborn screening for spinal muscular atrophy
By IPP Bureau - June 12, 2026
SENS study to assess feasibility, effectiveness and family experience of introducing SMA screening into the NHS newborn screening programme
Industry, regulators and quality experts discuss implementation of Indian Pharmacopoeia 2026
By IPP Bureau - June 12, 2026
Indian Pharmacopoeia Commission hosts scientific conclave to brainstorm on strengthening pharmaceutical quality and compliance
Research must translate into real-world solutions: Dr. Jitendra Singh
By IPP Bureau - June 12, 2026
Union Minister inaugurated a DST-funded Central Instrumentation Facility and three new research clusters focused on advanced materials, clean energy, and healthcare at IIT Gandhinagar
Narayana Health achieves HIMSS AMAM Stage 6, first in Indian subcontinent
By IPP Bureau - June 12, 2026
Recognition highlights the hospital network’s decade-long investment in analytics and AI-driven healthcare, supporting improved outcomes, efficiency, and affordability.
